Loading…
Employees: 39
Size Lumosa Therapeutics (6535.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $356M, the 580th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$70.20 on 6 Nov 2026.
Performance Over six months the shares fell 49.3%, against -21.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue fell 7.7% over the last twelve months (peer median +2.7%); the operating margin is -882.8% (peer median -16.3%).
Valuation It trades at 324.5× enterprise value to sales against a peer median of 4.3× (most expensive of 16).
Capital Return on invested capital runs 44.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$34.4M | NT$35.8M | NT$39.2M | NT$56.9M | NT$26.6M |
| Revenue growth | — | -8% | -31% | +114% | — |
| Gross profit | NT$16.8M | NT$21.8M | NT$17.6M | NT$24.8M | -NT$2.08M |
| EBITDA | -NT$292M | -NT$322M | -NT$349M | -NT$352M | -NT$284M |
| Net income | -NT$370M | -NT$341M | -NT$425M | -NT$238M | -NT$495M |
| Free cash flow | -NT$258M | -NT$357M | -NT$293M | -NT$335M | -NT$303M |
| Capital expenditure | NT$0 | NT$668,000 | NT$450,000 | NT$15.0M | NT$2.29M |
| Total debt | NT$3.48M | NT$6.92M | NT$8.48M | NT$12.6M | NT$4.69M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6535.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.4% | -10.9% | 6th lowest of 20 |
| 6-month return | -49.3% | -21.5% | 3rd lowest of 19 |
| Distance from 52-week high | -77.8% | -33.3% | lowest of 21 |
| Revenue growth (TTM) | -7.7% | +2.7% | 8th lowest of 19 |
| Operating margin | -882.8% | -16.3% | 2nd lowest of 17 |
| EV / Sales | 324.5× | 4.3× | most expensive of 16 |
| ROIC minus cost of capital | -44.0 pp | -11.5 pp | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | 29.9× | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | 22.0× | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | 22.9× | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 4.9× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | n/a | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | 46.9× | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | 1.1× | 4.2% | +3.1% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | 4.3× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |